YY Incorporation American Depository Receipt Repr 20 Shs Aktie

YY Incorporation American Depository Receipt Repr 20 Shs für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1J6W3 / ISIN: US98426T1060

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
03.03.2017 15:41:00

PriceWatch Alert: High return covered-call trades for Cliffs Natural Resources, JD.com, Realty Income, Ultragenyx Pharmaceuticals and YY

CHICAGO, March 3, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLF, JD, O, RARE, and YY.

To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts contain all the information needed to evaluate a new covered call, and/or a diagonal spread on the underlying stock. Each report has detailed explanations of the possible outcomes and risks for each trade, as well as an easy-to-read table that gives all the relevant metrics at a single glance.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pricewatch-alert-high-return-covered-call-trades-for-cliffs-natural-resources-jdcom-realty-income-ultragenyx-pharmaceuticals-and-yy-300417679.html

SOURCE InvestorsObserver

Analysen zu Realty Income Corp.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

JD.com Inc (spons. ADRs) 30,85 -1,59% JD.com Inc (spons. ADRs)
Realty Income Corp. 51,26 3,35% Realty Income Corp.
Ultragenyx Pharmaceutical Inc 31,00 -33,76% Ultragenyx Pharmaceutical Inc